175 related articles for article (PubMed ID: 36585521)
21. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas KM; Yang T; Buchan HL; Zhou P; Craig RW
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3516-20. PubMed ID: 7682708
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family.
Voutsadakis IA
Gene; 2023 Mar; 857():147179. PubMed ID: 36627096
[TBL] [Abstract][Full Text] [Related]
23. DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia.
Masetti R; Togni M; Astolfi A; Pigazzi M; Manara E; Indio V; Rizzari C; Rutella S; Basso G; Pession A; Locatelli F
Oncotarget; 2013 Oct; 4(10):1712-20. PubMed ID: 24127550
[TBL] [Abstract][Full Text] [Related]
24. BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
Chiou JT; Wu YY; Lee YC; Chang LS
Biochem Pharmacol; 2023 Sep; 215():115738. PubMed ID: 37562509
[TBL] [Abstract][Full Text] [Related]
25. [Pediatric de novo acute megakaryoblastic leukemia: an affair of complexes].
Lopez CK; Mercher T
Med Sci (Paris); 2018 Nov; 34(11):954-962. PubMed ID: 30526836
[TBL] [Abstract][Full Text] [Related]
26. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
27. Understanding MCL1: from cellular function and regulation to pharmacological inhibition.
Sancho M; Leiva D; Lucendo E; Orzáez M
FEBS J; 2022 Oct; 289(20):6209-6234. PubMed ID: 34310025
[TBL] [Abstract][Full Text] [Related]
28. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
Liu Y; Mondello P; Erazo T; Tannan NB; Asgari Z; de Stanchina E; Nanjangud G; Seshan VE; Wang S; Wendel HG; Younes A
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12034-12039. PubMed ID: 30404918
[TBL] [Abstract][Full Text] [Related]
29. Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.
Chen L; Chen W; Mysliwski M; Serio J; Ropa J; Abulwerdi FA; Chan RJ; Patel JP; Tallman MS; Paietta E; Melnick A; Levine RL; Abdel-Wahab O; Nikolovska-Coleska Z; Muntean AG
Leukemia; 2015 Jun; 29(6):1290-300. PubMed ID: 25650089
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors.
Voutsadakis IA
Gene; 2022 Dec; 847():146881. PubMed ID: 36100115
[TBL] [Abstract][Full Text] [Related]
31. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
[TBL] [Abstract][Full Text] [Related]
32. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
Cancer Biol Ther; 2009 Aug; 8(16):1587-95. PubMed ID: 19556859
[TBL] [Abstract][Full Text] [Related]
33. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
34. The selectivity of Marinopyrrole A to induce apoptosis in MCL1
Gomez-Bougie P; Dousset C; Descamps G; Schnitzler A; Audiger L; Tessier A; Dubreuil D; Lebreton J; Pellat-Deceunynck C; Amiot M
Br J Haematol; 2018 Jan; 180(1):157-159. PubMed ID: 27523575
[No Abstract] [Full Text] [Related]
35. MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells.
Bottardi S; Guieze R; Bourgoin V; Fotouhi-Ardakani N; Dougé A; Darracq A; Lakehal YA; Berger MG; Mollica L; Bay JO; Omichinski JG; Milot E
Exp Hematol; 2020 Aug; 88():68-82.e5. PubMed ID: 32682001
[TBL] [Abstract][Full Text] [Related]
36. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
[TBL] [Abstract][Full Text] [Related]
37. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
Mallick DJ; Soderquist RS; Bates D; Eastman A
Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
[TBL] [Abstract][Full Text] [Related]
38. Antiapoptotic signaling via MCL1 confers resistance to caspase-3-mediated apoptotic cell death in the pregnant human uterine myocyte.
Stephenson-Famy A; Marks J; Suresh A; Caritis SN; Simhan H; Jeyasuria P; Condon JC
Mol Endocrinol; 2012 Feb; 26(2):320-30. PubMed ID: 22194343
[TBL] [Abstract][Full Text] [Related]
39. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
